Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)
试验速览
- 阶段
- 2 期
- 入组人数
- 21
- 试验地点
- 4
- 主要终点
- Change of dystrophin expression rate in muscle tissues from the baseline assessment
研究概览
简要总结
Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 4 Years 至 —（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of DMD resulting from a nonsense mutation by whole genome sequencing of the dystrophin gene
- •To have intact right or left biceps muscles, or an alternative muscle group that is able to be underwent for appropriate evaluation of efficacy
- •To meet the following criteria at screening (baseline visit), within 30 days prior to the first dose of study drug
- •Ambulant and able to walk at least 75 meters during the 6MWT
- •Able to comply with and complete all protocol requirements, and judged by the investigator to be appropriate to participate in the study from the screening results
- •Aged at least 4 years at the time of giving informed consent
- •Able to be hospitalized for the study requirement
- •Signed Informed consent by parents/legal guardian and/or signed assent by the subject (age of assent to be determined by IRB)
排除标准
- •Prior exposure to investigational medicines that have a potential of restoring dystrophin or other functional protein (readthrough, exon skipping, utrophin upregulation therapy etc.)
- •Known mutation at nucleotide 1555 in 12S rRNA gene of mitochondrial DNA, and/or personally or families have been treated or have a history of eight cranial nerve disorder （hearing loss、vertigo、tinnitus etc.）as a result of aminoglycoside use
- •Inability to hear within the range of 0 to 25 dB by pure tone audiometry, abnormalities on auditory brainstem response audiometry, and/or loss of frequency by distortion product oto acoustic emissions at screening
- •Poor oral intake or enable to oral intake, and/or bad general status
- •Known allergies to NPC-14, other aminoglycosides, and/or bacitracin
- •Presence of anti-dystrophin antibody at the baseline assessments
- •Cys-C ≥1.2 mg/L and/or creatinine concentration >1.5 times the upper limit of age corrected normal range
- •Left ventricular ejection fraction (EF) <40% or left ventricular fractional shortening (FS) <25%, and/or ≥480 msec QTc (corrected QT interval by Fridericia's method)
- •Need of mechanical ventilation
- •Forced vital capacity (FVC) <50% predicted
- •Clinically significant concomitant diseases (hematology, psychoneurotic, hepatic, pulmonary, endocrine, immune, renal, and gastroenterological diseases), and/or cancer
- •Impairment of intellectual functions, and/or expressive language ability which might interfere with study assessments
- •Treatment with other systemic aminoglycoside within 6 months prior to the first administration of study drug
- •Initiation of systemic glucocorticosteroids treatment, and/or start exercise cure, physical therapy, or occupational therapy which might interfere with study assessments. Changing of dose and schedule of systemic glucocorticosteroids within 6 months prior to the first administration of study drug
- •History of any surgical procedure within months prior to the first administration of study drug or have a plan during study
- •History of sever allergy from food and medicine like an anaphylaxis shock or generalized rash
- •Participation in any other clinical trial and intake of any investigational drug within 6month of study entry
研究组 & 干预措施
NPC-14
Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
干预措施: NPC-14 (Drug)
Placebo
Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
干预措施: Placebo (Drug)
结局指标
主要结局
Change of dystrophin expression rate in muscle tissues from the baseline assessment
时间窗: At 37 weeks (1 week after from 36 weeks treatment period)
Safety and tolerability (Adverse events)
时间窗: Up to 38 weeks (36 weeks treatment period and 2 weeks follow up period)
次要结局
- North Star Ambulatory Assessment(At 36 weeks)
- Timed test (6MWT, time to walk/run 10 meters, time to climb/descent four steps, time to rise from the floor)(At 36 weeks)
- Dairy activities(At 36 weeks)
- Muscle strength (MMT, QMT)(At 36 weeks)
- Biomarkers (CK, ALD)(At 36 weeks)
研究者
Yasuhiro Takeshima
MD, PhD
Kobe University